Information for C/T Blend

C/T Blend is a blend between Cagrilintide and Tirzepatide.

Cagrilintide is a long-acting amylin analogue, developed as a successor to earlier versions like pramlintide. This compound is designed with an extended half-life and aims to address protein aggregation challenges observed in previous amylin analogues. Amylin, the natural counterpart, is a peptide produced by pancreatic beta cells and interacts with various body systems. Researchers are currently exploring Cagrilintide's potential, particularly in combination with other compounds like semaglutide, for its effects on appetite regulation and weight management.

Tirzepatide was developed to fight type 2 diabetes, but has additionally been shown to protect the cardiovascular system and act as a potent weight loss agent. Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality as well.